Sphera Funds Management LTD. Sells 48,000 Shares of Zura Bio Limited (NASDAQ:ZURA)

Sphera Funds Management LTD. trimmed its holdings in shares of Zura Bio Limited (NASDAQ:ZURA) by 6.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 690,718 shares of the company’s stock after selling 48,000 shares during the quarter. Sphera Funds Management LTD. owned about 1.06% of Zura Bio worth $1,727,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of ZURA. Barclays PLC increased its position in Zura Bio by 777.1% during the third quarter. Barclays PLC now owns 64,061 shares of the company’s stock worth $260,000 after acquiring an additional 56,757 shares during the period. SG Americas Securities LLC increased its holdings in Zura Bio by 51.6% in the 4th quarter. SG Americas Securities LLC now owns 23,005 shares of the company’s stock valued at $58,000 after buying an additional 7,828 shares during the period. Rhumbline Advisers increased its holdings in Zura Bio by 37.3% in the 4th quarter. Rhumbline Advisers now owns 37,657 shares of the company’s stock valued at $94,000 after buying an additional 10,231 shares during the period. Raymond James Financial Inc. bought a new position in Zura Bio in the 4th quarter valued at about $371,000. Finally, American Century Companies Inc. bought a new position in Zura Bio in the 4th quarter valued at about $27,000. 61.14% of the stock is owned by institutional investors.

Zura Bio Trading Up 2.6%

ZURA opened at $1.20 on Friday. The company’s 50 day moving average is $1.28 and its 200-day moving average is $2.02. Zura Bio Limited has a 1-year low of $0.97 and a 1-year high of $6.35. The company has a market cap of $82.05 million, a P/E ratio of -1.71 and a beta of 0.05.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). On average, equities analysts forecast that Zura Bio Limited will post -0.65 EPS for the current year.

Analyst Ratings Changes

Several research firms have commented on ZURA. Chardan Capital decreased their target price on shares of Zura Bio from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, March 26th. Oppenheimer decreased their target price on shares of Zura Bio from $19.00 to $17.00 and set an “outperform” rating on the stock in a report on Friday, May 9th. Guggenheim reissued a “buy” rating and issued a $15.00 target price on shares of Zura Bio in a report on Wednesday, March 26th. Finally, HC Wainwright reissued a “buy” rating on shares of Zura Bio in a report on Thursday, April 3rd. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $14.33.

Zura Bio Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.